Interferon-α mechanism of action in MPN

Current understanding

To be populated as evidence accumulates.

2026-09-15 — Type 1 interferon perturbates clonal competition by reshaping human blood development.: cross-connection with ropeginterferon-besremi: Single-cell multiomic evidence that IFNα depletes CALR/JAK2-mutant clones by polarizing HSCs into lymphoid vs inflammatory-myeloid fates directly supplements the mechanism-of-action page underlying ropeginterferon’s clinical activity. (novelty: 4)
2026-09-01 — Type-I interferon-activated NK cells control polycythemia vera in vivo.: cross-connection with ciml-nk-cell-immunotherapy-mpn: IFN-α mechanism in MPN converges on NK-cell activation and TNF-α-mediated mutant HSPC killing, linking the IFN mechanism page to NK-cell therapy strategies. (novelty: 5)
2026-06-02 — Genomic insights transform diagnosis, prognosis, and therapy in BCR::ABL1-negative myeloproliferative neoplasms.: Review (review-level) reinforces interferon-α as a disease-modifying, clone-directed therapy in BCR::ABL1-negative MPN and proposes mechanism-aligned molecular monitoring (e.g., platelet-derived CREB3L1 mRNA expression) beyond pathway-level cytoreduction. (novelty: 3)